Article: Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy.
2023 Volume 14, Page(s) 970457
Abstract: ... other proliferating cells. Given the importance of T cells in antitumor defense, we studied the influence ... of palbociclib/fulvestrant on human CD3+ T cells and novel emerging T cell-based cancer immunotherapies ... Palbociclib considerably inhibited the proliferation of activated T cells by mediating G0/G1 cell cycle arrest ...
| Abstract | The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor (Her)2-negative breast cancer in combination with the ER degrader fulvestrant. However, CDK4/6 inhibitors are not cancer-specific and may affect also other proliferating cells. Given the importance of T cells in antitumor defense, we studied the influence of palbociclib/fulvestrant on human CD3+ T cells and novel emerging T cell-based cancer immunotherapies. Palbociclib considerably inhibited the proliferation of activated T cells by mediating G0/G1 cell cycle arrest. However, after stopping the drug supply this suppression was fully reversible. In light of combination approaches, we further investigated the effect of palbociclib/fulvestrant on T cell-based immunotherapies by using a CD3-PSCA bispecific antibody or universal chimeric antigen receptor (UniCAR) T cells. Thereby, we observed that palbociclib clearly impaired T cell expansion. This effect resulted in a lower total concentration of interferon-γ and tumor necrosis factor, while palbociclib did not inhibit the average cytokine release per cell. In addition, the cytotoxic potential of the redirected T cells was unaffected by palbociclib and fulvestrant. Overall, these novel findings may have implications for the design of treatment modalities combining CDK4/6 inhibition and T cell-based cancer immunotherapeutic strategies. |
|---|---|
| Language | English |
| Publishing date | 2023-02-03 |
| Publishing country | Switzerland |
| Document type | Journal Article |
| ZDB-ID | 2587355-6 |
| ISSN | 1663-9812 |
| ISSN | 1663-9812 |
| DOI | 10.3389/fphar.2023.970457 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.